

ICAA CONFERENCE 2018

The 6th International Cerebral Amyloid Angiopathy & related disorders Conference

PROGRAM

Thursday, September 6th 2018

Session 1 9:00-12:45

9:00 Official opening of the conference

Dean Gosset

HCHWA-D

Moderators: Mark van Buchem (Leiden, NL)
& Gaël Nicolas (Rouen, FR)

9:15 Introductory talk

Jolanda Blom (HCHWA-D Patient Organization)

9:25 Imaging markers of presymptomatic HCHWA-D patients.

Sanneke van Rooden (Leiden, NL)

9:55 Anti-sense oligonucleotide treatment in HCHWA-D.

Willeke van Roon (Leiden, NL)

10:25 Hereditary cerebral amyloid angiopathy (HCAA)-type mutations increase β -amyloid's binding affinity for fibrinogen, delayed fibrinolysis, and fibrin deposit formation in the brains of HCAA patients

Hyung Jin Ahn (New-York, USA)

10:35 CO₂-challenge measured with dual echo arterial spin labeling as a whole brain biomarker of cerebrovascular reactivity in HCHWA-D

Sophie Schmid (Leiden, NL)

10:45 Coffee Break

11:15 PiB-PET imaging in HCHWA-D in Australia and the Netherlands.

Jasmeer Chhatwal (Boston, MA, USA)

11:45 Candidate therapy studies for Icelandic-type hereditary CAA

Hakon Hakonarson (Philadelphia, PA, USA)

12:15 Cerebral amyloid angiopathy influences clinical phenotype in familial Alzheimer's disease

Natalie S Ryan (London, UK)

12:25 Imaging characteristics of duplication of the app

Lou Grangeon (Rouen, France)

12:35 Feasibility of an active immunization clinical trial with a vaccine targeting amyloid- β vaccine in patients with HCHWA-D.

Kawita Kanhai

Moderators: Hameed Sohradi (Perth, AU)
& Marieke Wermer (Leiden, NL)

12:45 Lunch Break



INTERNATIONAL
caa
ASSOCIATION



Université
de Lille



CHU
LILLE



Session 2

2:00- 5:30pm

Biomarkers of CAA

Moderators: *Fabrizio Piazza (Milan, IT)*
& *Susanna Schraen (Lille, FR)*

2:00 MRI Correlates of Autopsy-proven CAA

Konstantinos Arfanakis (Chicago, IL, USA)

2:30 New Insights from PET Molecular Imaging of CAA

Anand Viswanathan (Boston, MA, USA)

3:00 Blood-brain barrier leakage and microvascular lesions in cerebral amyloid angiopathy - A post mortem MRI and histopathology study

Whitney M. Freeze (Boston, USA)

3:10 Evidence for human transmission of amyloid- β cerebral amyloid angiopathy

Zane Jaunmuktane (London, UK)

3:20 Comparing whole-brain susceptibility patterns in patients with Alzheimer's disease & cerebral amyloid angiopathy: a QSM study.

V. Perosa (Magdeburg, Germany)

3:30 Coffee Break

4:00 Novel body fluid biomarkers for CAA: discovery and clinical implications

Marcel Verbeek (Nijmegen, NL)

4:30 Biomarkers of Cognitive Dysfunction in CAA

Yael Reijmer (Utrecht, NL)

5:00 Blood Metabolomic Profiling in Cerebral Amyloid Angiopathy, Alzheimer's Disease, and Controls

Shuang Zhao (Alberta, Canada)

5:10 Cerebellar Hemorrhagic Distribution as a New Imaging Marker for Cerebral Amyloid Angiopathy

Hsin-Hsi Tsa i (Taipei, Taiwan)

5:20 "Blood begets blood": Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy

Thanakit Pongpitakmetha (Boston, USA)

Moderators: *Grégoire Boulouis (Paris, FR),*
& *Miyeko Vernooij (NL)*

5:30 End of the day

8:30 Gala dinner



INTERNATIONAL
caa
ASSOCIATION



Université
de Lille



CHU
LILLE

Lille FHU-VasCog
UNIVERSITY HOSPITAL OF VASCULAR COGNITIVE
DISORDERS

LICEND
LILLE CENTER OF EXCELLENCE
IN THE MANAGEMENT OF DEMENTIAS

ADRINORD

Friday, September 7th 2018

Session 3 9:00-12:30

CAA Biology and Physiology

Moderators: *Susanne van Veluw (Boston, USA)*
& *Vincent Berezowski (Lille, FR)*

9:00 Effect of biological variants of ApoJ and ApoA-I in experimental models of cerebral β -amyloidosis

Mar Hernandez-Guillamon (Barcelona, ES)

9:30 Vasoactive properties of amyloid β isoforms correlate with their specific expression in CAA

Lieke Jäkel (Nijmegen, NL)

10:00 Silent cerebral microbleeds induce long-term cognitive decline in the non-diseased mouse

Maud Pétrault (Lille, France)

10:10 Connexin 43 and Cx43-20kDa isoform lead to vascular injury in cerebral amyloid angiopathy

Svetlana M Stamatovic, (Ann Arbor MI, USA)

10:20 Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy

H. Bea Kuiperija (Nijmegen, The Netherlands)

10:30 Coffee Break

11:00 Artificial vessels as a model for CAA

Cheryl Wellington (Vancouver, CA)

11:30 Characterization of a novel transgenic rat model for CAA

William van Nostrand, (Kingston, RI, USA)

12:00 Perlecan Domain V as a Novel Treatment for Diabetic Co-morbid Experimental CAA

Amanda Trout, Anika Hartz, Gregory Bix (Lexington, KY)

12:10 Reduced vessel reactivity in mice with vascular A β deposition is associated with impaired paravascular clearance

Susanne J. van Veluw (Boston, USA)

12:20 Cerebrovascular smooth muscle cells as the drivers of periarterial lymphatic drainage of the brain

Roxana Aldea, (University of Kentucky, USA)

Moderators: *Roxana Carare (Southampton, UK)*
& *R. Bordet (Lille)*

12:30 Lunch break

Session 4 2:00-3.30pm

Clinical Implications and Therapeutic Dilemmas

Moderator: *Karin Klijn (Nijmegen, NL) and Edip Gurof (Boston, USA)*

2:00 Can we anticoagulate CAA patients in the context of atrial fibrillation?

Rustam Al-Shahi Salman (Edinburgh, UK)

2:30 Cognitive impairment in CAA patients: towards a diagnostic and therapeutic approach?

Jérémie Pariente (Toulouse, FR)

3:00 A Cohort Study on the Natural History of Cerebral Amyloid Angiopathy-related inflammation: Evaluation of the Long-Term Outcomes of Immunosuppressive Therapy.

Fabrizio Piazza (Milano, Italy)

3:10 Serum anti-A β antibody signatures in cerebral amyloid angiopathy manifestations

Yannick Chantran (Paris, France)



INTERNATIONAL
caa
ASSOCIATION



Université
de Lille



CHU
LILLE



LICEND
LILLE CENTRE OF EXCELLENCE
FOR NEURODEGENERATIVE DISEASES



3:20 Cognitive profile of MCI patients with cerebral amyloid angiopathy
An ancillary study of the BALTAZAR cohort
Buard Géraldine(Lille, France)

15:30 Coffee Break

4:00 Transient focal neurological episodes: how to recognize and how to treat?
Speaker: Eric Smith (Calgary, CA)

4:30 The difficult diagnosis of CAA related inflammation

Part 1: Diagnosis

Speaker: Auriel Eytan (Tel Aviv, Israel)

Part 2: Treatment

Speaker: Sonia Alamowitch (Paris, FR)

5:00 Poster walk

Moderators: Grégoire Kuchcinsky (Lille, FR) and Ellis van Etten (Leiden, NL)

5:30 End of the day



INTERNATIONAL
caa
ASSOCIATION

CAA
DUTCH CAA FOUNDATION

**Université
de Lille**



**CHU
LILLE**

Lille FHU-VasCog
Lille - Angers - Bordeaux - Montpellier - Nancy

LiCEND
LILLE CENTER OF EXCELLENCE
FOR NEURODEGENERATIVE DISEASES

ADRINORD

Saturday, September 8th 2018

Session 5 9:00-12:30

10:30 Coffee Break

Emerging Diagnostic Methods for CAA

Moderators: Steve Greenberg (Boston, USA)
&Stephanie Bombois (Lille, FR)

9:00 CT-based criteria for CAA

Mark Rodrigues (Edinburgh, UK)

9:30 Guidelines for cortical superficial siderosis detection, rating and classification

Frank Wollenweber (Munich, DE)

10:00 Subarachnoid extension of lobar hemorrhage on MRI in the acute and subacute phase is associated with the presence of criteria of probable cerebral amyloid angiopathy

Dimitri Renard (Nimes, France)

10:10 Blood begets blood": Cortical superficial siderosis progression in a prospective cohort of cerebral amyloid angiopathy

Thanakit Pongpitakmetha (Boston, USA)

10:20 Cerebellar microbleeds distribution and cerebral amyloid angiopathy: an MRI and pathology-based study

Marco Pasi (Boston, USA)

11:00 Incidence of cerebral microbleeds and amyloid burden: the Mayo Clinic Study of Aging
Jonathan Graff-Radford (Mayo Clinic, USA)

11:10 Texture-based Individual-level Classification of Normal-Appearing White Matter and White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Healthy Controls

Klourfeld E (Calgary, Canada)

11:20 Pathologic lesions associated with clinical impairment

Julie Schneider (Chicago, IL, USA)

11:50 Boston Criteria version 2.1

Andreas Charidimou (Boston, MA, USA)

Moderators: David Werring (London, UK) and Sarah Shams (Stockholm, SE)

12:30 Conclusion & iCAA 2020

12:45 End of the conference

This conference is supported by



This meeting is endorsed by the European Stroke Organization.

It is open to all who are interested in cerebrovascular diseases.

<http://www.eso-stroke.org/>

Link to the next ESO Conference: <http://eso.kenes.com/>